If you have been reading about lipogenesis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
=== Active site === The cleft between GALE's N- and C-terminal domains constitutes the enzyme's active site. A conserved Tyr-X-X-X Lys motif is necessary for GALE catalytic activity; in humans, this motif is represented by Tyr 157-Gly-Lys-Ser-Lys 161, while E. coli GALE contains Tyr 149-Gly-Lys-Ser-Lys 153. The size and shape of GALE's active site varies across species, allowing for variable GALE substrate specificity. Additionally, the conformation of the active site within a species-specific GALE is malleable; for instance, a bulky UDP-GlcNAc 2' N-acetyl group is accommodated within the human GALE active site by the rotation of the Asn 207 carboxamide side chain.
As distressing as these border conflicts were, the Polish–Soviet War of 1919–1921 was the most important series of military actions of the era. Piłsudski had entertained far-reaching anti-Russian cooperative designs in Eastern Europe, and in 1919 the Polish forces pushed eastward into Lithuania, Belarus and Ukraine by taking advantage of the Russian preoccupation with a civil war, but they were soon confronted with the Soviet westward offensive of 1918–1919. Western Ukraine was already a theater of the Polish–Ukrainian War, which eliminated the proclaimed West Ukrainian People's Republic in July 1919. In the autumn of 1919, Piłsudski rejected urgent pleas from the former Entente powers to support Anton Denikin's White movement in its advance on Moscow. The Polish–Soviet War proper began with the Polish Kiev offensive in April 1920. Allied with the Directorate of Ukraine of the Ukrainian People's Republic, the Polish armies had advanced past Vilnius, Minsk and Kiev by June. At that time, a massive Soviet counter-offensive pushed the Poles out of most of Ukraine. On the northern front, the Soviet army reached the outskirts of Warsaw in early August. A Soviet triumph and the quick end of Poland seemed inevitable. However, the Poles scored a stunning victory at the Battle of Warsaw (1920). Afterwards, more Polish military successes followed, and the Soviets had to pull back. They left swathes of territory populated largely by Belarusians or Ukrainians to Polish rule. The new eastern boundary was finalized by the Peace of Riga in March 1921.
The continental policy of England [after 1525] was fixed. It was to be pacific, mediating European affairs, favorable to a balance which should prevent any power from having a hegemony on the continent or controlling the Channel coasts. The naval security of England and the balance of power in Europe were the two great political principles which appeared in the reign of Henry VIII and which, pursued unwaveringly, were to create the greatness of England. In 1579, the first English translation of Francesco Guicciardini's Storia d'Italia ("History of Italy") popularised the Italian balance of power theory in England. This translation was dedicated to Elizabeth I of England and claimed that "God has put into your hand the balance of power and justice, to poise and counterpoise at your will the actions and counsels of all the Christian kings of your time". Thomas Carlyle referred to statesmen "in shadow-hunting, shadow-hunted hour ... looking with intense anxiety into a certain spectral something they call the Balance of Power." Statesman Richard Cobden labeled the balance of power "a chimera" due to its unclear meaning: "It is not a fallacy, a mistake, an imposture—it is an undescribed, indescribable, incomprehensible nothing." The only point on which writers on the balance of power agree "is in the fundamental delusion that such a system was ever acceded to by the nations of Europe." They imply long, uninterrupted, peaceful and prosperous co-existence.
== Later research == Later research projects conducted by Leeman and her lab were centered around the two peptides, substance P and neurotensin, that she originally isolated, sequenced, and synthesized. Her lab at Boston University has multiple goals regarding these neural peptides, including mapping their distribution within the brain and peripheral nervous system, delineating tracts containing substance P or neurotensin within the central nervous system, determining how substance P and neurotensin are released from neural tissue in vitro and in vivo, and identifying the binding domain of substance P with its receptor.
Sources: en.wikipedia.org
== Choice of base formulation == A medication's potency often is changed with its base. For example, some topical steroids will be classified one or two strengths higher when moving from cream to ointment. As a rule of thumb, an ointment base is more occlusive and will drive the medication into the skin more rapidly than a solution or cream base. The manufacturer of each topical product has total control over the content of the base of a medication. Although containing the same active ingredients, one manufacturer's cream might be more acidic than the next, which could cause skin irritation or change its absorption rate. For example, a vaginal formulation of miconazole antifungal cream might irritate the skin less than an athlete's foot formulation of miconazole cream. These variations can, on occasion, result in different clinical outcomes, even though the active ingredient is the same. No comparative potency labeling exists to ensure equal efficacy between brands of topical steroids (percentage of oil vs water dramatically affect the potency of topical steroid). Studies have confirmed that the potency of some topical steroid products may differ according to manufacturer or brand. An example of this is the case of brand name Valisone cream and Kenalog cream in clinical studies have demonstrated significantly better vasoconstrictions than some forms of this drug produced by generic drug manufacturers. However, in a simple base like an ointment, much less variation between manufacturers is common.
=== Scientific journal articles === Holick, MF (2007). "Vitamin D deficiency". N Engl J Med. 357 (3): 266–81. doi:10.1056/NEJMra070553. PMID 17634462. S2CID 18566028. Holick, MF (2006). "Resurrection of vitamin D deficiency and rickets". J Clin Invest. 116 (8): 2062–72. doi:10.1172/JCI29449. PMC 1523417. PMID 16886050. Pietras, SM; Obayan, BK; Chai, MH; Holick, MF (2010). "Vitamin D2 treatment for vitamin D deficiency and insufficiency for up to 6 years". Arch Intern Med. 169 (19): 1806–8. doi:10.1001/archinternmed.2009.361. PMID 19858440. Biancuzzo, RM; Young, A; Bibuld, D; Cai, MH; Winter, RM; Klein, EK; Ameri, A; Reitz, R; Salameh, W; Chen, TC; Holick, MF (2010). "Fortification of orange juice with vitamin D(2) or vitamin D(3) is as effective as an oral supplement in maintaining vitamin D status in adults". Am J Clin Nutr. 91 (6): 1621–6. doi:10.3945/ajcn.2009.27972. PMC 2869510. PMID 20427729. Holick, MF; Binkley, NC; Bischoff-Ferrari, HA; Gordon, CM; Hanley, DA; Heaney, RP; Murad, MH; Weaver, CM; et al. (2011). "Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline". J Clin Endocrinol Metab. 96 (7): 1911–30. doi:10.1210/jc.2011-0385. PMID 21646368.
R-30490 (also known as 4-methoxymethylfentanyl) is an opioid analgesic related to the highly potent animal tranquilizer carfentanil, and with only slightly lower potency. It was first synthesised by a team of chemists at Janssen Pharmaceutica led by Paul Janssen, who were investigating the structure-activity relationships of the fentanyl family of drugs. R-30490 was found to be the most selective agonist for the μ-opioid receptor out of all the fentanyl analogues tested, but it has never been introduced for medical use in humans, although the closely related drug sufentanil is widely used for analgesia and anesthesia during major surgery. Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.
Sources: en.wikipedia.org
While Operation Hooper was underway in late January 1988, Crocker relented to pressure and accepted Cuba as an equal partner in further peace talks. Castro agreed that he would not introduce extraneous issues to the agenda, such as Cuba–US relations, and that discussion of a phased troop withdrawal would extend to all Cuban military personnel stationed in Angola, including combat troops, logistical staff, and advisers. With Cuba's entry into the Brazzaville talks, its desire to shift its military involvement in Angola from a passive, defensive role to an offensive one intensified. Castro opted to escalate ground operations against the SADF, since he considered diplomatic progress impossible as long as South Africa still clung to the likelihood of a tactical victory. He retained a solely defensive posture at Cuito Cuanavale, keeping the SADF fixed in place, while carrying out his longstanding proposal to launch a flanking manoeuvre towards the South West African border. The new offensive would consist of a movement of Cuban forces in divisional strength west of the Cunene River. On 9 March, Castro ordered all Cuban troops massed at Lobito, which had grown to about 40,000 men, southward. He likened their movement to "a boxer who with his left hand blocks the blow [at Cuito Cuanavale] and with his right – strikes [in the west]".
omics A suffix used to describe any of the diverse fields of study that conduct rigorous, systematic analyses of any of the "omes", e.g. the genome, transcriptome, proteome, metabolome, etc., each of which represents the totality of a specific class of biological content that has been or could hypothetically be isolated from an individual cell, population of cells, organism, species, or some other particular context. Thus genomics is the field of study which analyzes the totality of genes in a genome, proteomics studies the complete set of all of the proteins in a proteome, etc. The term may also be used to refer to all of these fields collectively.
Tolkien was a devout Roman Catholic. He was a significant factor in C. S. Lewis's conversion from atheism to Christianity. He once wrote to Rayner Unwin's daughter Camilla, who wished to know the purpose of life, that it was "to increase according to our capacity our knowledge of God by all the means we have, and to be moved by it to praise and thanks." Tolkien had a special devotion to the blessed sacrament, writing to his son Michael that in "the Blessed Sacrament ... you will find romance, glory, honour, fidelity, and the true way of all your loves upon earth, and more than that". He accordingly encouraged frequent reception of Holy Communion, again writing to his son Michael that "the only cure for sagging of fainting faith is Communion." He believed the Catholic Church to be true most of all because of the pride of place and the honour in which it holds the Blessed Sacrament. In the last years of his life Tolkien resisted certain liturgical changes implemented after the Second Vatican Council, his primary objection being the use of English for the liturgy. Tolkien spoke Latin fluently, and he felt that the English translations were clumsy. In his old age he continued to make the Mass responses in Latin. Tolkien did not sign the Agatha Christie indult, however, and he served as a lector at Corpus Christi, a parish church in Headington, in accordance with the allowances of the Council.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.